measles + rubella vaccine

The measles and rubella (MR) vaccine is a live-attenuated viral vaccine combination designed to induce active immunity against measles (caused by Measles morbillivirus) and rubella (caused by Rubella virus). It is a standard component of pediatric immunization schedules globally. In the context of clinical research led by PATH, such as the evaluation of the R21/Matrix-M malaria vaccine, the MR vaccine is utilized as a routine intervention in Phase 2b trials. These studies assess the safety and immunogenicity of the malaria vaccine when integrated into the standard Expanded Programme on Immunization (EPI) schedule, which includes the MR vaccine typically administered at 9 months of age. The MR vaccine used in these settings is often a WHO-prequalified product, such as those manufactured by the Serum Institute of India, containing at least 1000 CCID50 of each viral component per 0.5 mL dose.

Other names

measles + rubella vaccine-PATH-malariaMeasles and Rubella VaccineMR